Humana Inc Stock Fair Value – Cantor Fitzgerald Reiterates “Neutral” Rating for Humana in Recent Stock Report
October 5, 2024
🌥️Trending News
Humana Inc ($NYSE:HUM). is a leading health insurance company in the United States, providing a wide range of healthcare services to its customers. Humana offers a variety of health insurance plans and services, including Medicare, Medicaid, and commercial plans, as well as specialty services such as dental, vision, and long-term care coverage. This means that they do not have a strong opinion on whether investors should buy or sell the stock, and it is expected to perform in line with the overall market. The report highlighted Humana’s position as a strong player in the healthcare industry, with a solid track record of financial performance and customer satisfaction. Cantor Fitzgerald also noted some potential risks for Humana, such as changes in government policies and regulations, which could impact the company’s profitability and growth prospects.
However, they also emphasized Humana’s strong financial position and diverse portfolio of healthcare offerings as factors that could help mitigate these risks. The neutral rating from Cantor Fitzgerald may not come as a surprise to some investors, as analysts have been divided on Humana’s stock in recent months. While some have given the stock a positive outlook, others have raised concerns about potential challenges facing the healthcare industry, such as rising medical costs and competition from other insurance providers. However, it has experienced some fluctuations in recent months due to market conditions and industry developments. As the healthcare landscape continues to evolve, investors will likely keep a close eye on Humana’s performance and heed the advice of analysts such as Cantor Fitzgerald in making decisions about their investments. In conclusion, Humana Inc. remains a key player in the healthcare industry, with a strong reputation and a diverse portfolio of products. While Cantor Fitzgerald maintains a neutral stance on the stock, investors should carefully consider all factors before making any decisions regarding Humana’s stock in the coming months.
Price History
Cantor Fitzgerald, a financial services firm, has reiterated its “Neutral” rating for Humana Inc. in their recent stock report. This comes after the company’s stock opened at $316.08 and closed at $319.57 on Friday, showing a 2.09% increase from the previous closing price of $313.04. The “Neutral” rating indicates that the financial services firm does not have a strong opinion on the company’s stock performance and suggests that investors should hold onto their current positions rather than buy or sell. This rating is based on various factors such as the company’s financial stability, market trends, and potential for growth. In the case of Humana Inc., the stock’s recent performance has been positive, with a slight increase in value from the previous closing price. This could be attributed to the company’s strong financial standing and its position as one of the largest health insurance providers in the United States. Additionally, Humana has been making strategic acquisitions and partnerships to expand its reach and offerings, which could lead to future growth.
However, despite these positive factors, Cantor Fitzgerald has maintained a neutral stance on Humana Inc. This could be due to the uncertainty surrounding the healthcare industry, especially with potential changes to healthcare policies and regulations. As a leading health insurance provider, Humana could be affected by any major shifts in government policies. In conclusion, while Humana Inc.’s recent stock performance has been positive, Cantor Fitzgerald’s “Neutral” rating suggests that investors should carefully consider all factors before making any decisions regarding their positions. The financial services firm will continue to monitor the company’s performance and provide updates as needed. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Humana Inc. More…
| Total Revenues | Net Income | Net Margin |
| 106.37k | 2.49k | 2.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Humana Inc. More…
| Operations | Investing | Financing |
| 3.98k | -3.49k | -856 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Humana Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 47.06k | 30.75k | 132.09 |
Key Ratios Snapshot
Some of the financial key ratios for Humana Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 11.3% | – | 3.6% |
| FCF Margin | ROE | ROA |
| 2.8% | 14.6% | 5.1% |
Analysis – Humana Inc Stock Fair Value
As a team at GoodWhale, we recently conducted a thorough analysis of HUMANA INC‘s fundamentals, and we wanted to share our findings with our readers. After evaluating various factors such as financial performance, industry trends, and market conditions, we have determined that the fair value of HUMANA INC’s share is around $562.1. This value was calculated using our proprietary Valuation Line, which takes into account a range of metrics to determine the true worth of a company’s stock. However, currently, HUMANA INC’s stock is being traded at $319.57, which means it is undervalued by a significant 43.1%. This indicates that there is potential for the stock to increase in value and presents a potential buying opportunity for investors. Our analysis found that HUMANA INC has strong fundamentals, with a solid financial performance and a strong position in the healthcare industry. We also took into consideration the current market conditions, including any potential risks and challenges that could impact the company’s future growth. Ultimately, our evaluation has led us to believe that HUMANA INC’s stock is currently undervalued and has the potential to generate strong returns for investors. As with any investment, it is important to conduct further research and carefully consider all factors before making a decision. However, we believe that HUMANA INC has strong fundamentals and presents an attractive opportunity for investors looking to add a solid healthcare company to their portfolio. More…
Peers
In the ever-changing world of healthcare, Humana Inc. has been a leader in providing quality services to its customers. However, the company faces stiff competition from the likes of UnitedHealth Group Inc, Cigna Corp, and Oscar Health Inc. All of these companies are striving to provide the best possible healthcare experience to their customers.
– UnitedHealth Group Inc ($NYSE:UNH)
UnitedHealth Group Inc. is an American for-profit managed health care company based in Minnetonka, Minnesota. It is the largest healthcare company in the world by revenue, with 2019 revenue of $242.2 billion. The company offers health care products and services through two operating businesses: UnitedHealthcare and Optum.
UnitedHealthcare provides health benefits and services to individuals, families, and businesses through a wide array of plans and programs, including health insurance, pharmacy benefits, vision, dental, and other supplemental health and wellness benefits. Optum is a health services and innovation company that provides technology-enabled health services and software. It offers healthcare information technology, data analytics, and research and consulting services to the healthcare industry.
The company has a market capitalization of $488.16 billion as of April 2021 and a return on equity of 21.75%.
– Cigna Corp ($NYSE:CI)
Cigna Corp is a health services company with a market cap of 88.46 billion as of 2022. The company has a return on equity of 11.01%. Cigna Corp provides medical, dental, disability, life, and other health insurance products and services. The company also offers pharmacy benefit management services.
– Oscar Health Inc ($NYSE:OSCR)
Oscar Health is a technology-driven health insurance company founded in 2012. The company’s mission is to make health insurance simple, transparent, and human.
Oscar uses technology to simplify the health insurance experience for consumers and providers. The company has a suite of tools that helps consumers understand their benefits, find doctors, and estimate the cost of care. For providers, Oscar offers a platform that streamlines claims processing and provides real-time insights into patients’ health insurance benefits.
Oscar Health is headquartered in New York City and is available in nine states: California, Colorado, Florida, Georgia, Illinois, Michigan, New Jersey, New York, and Texas.
Summary
Investment analysts at Cantor Fitzgerald have reissued a “neutral” rating for Humana’s stock, indicating that they believe the stock will perform in line with the overall market. This reaffirmation of rating reflects the analysts’ assessment of Humana’s financial performance and potential for growth. It also suggests that there are no significant factors currently driving the stock up or down. This information can be useful for investors considering adding Humana to their portfolio, as it provides a neutral outlook and can serve as a starting point for further research and analysis of the company’s financials and market trends.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
